Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: EyePoint (EYPT) - EyePoint currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for potential outperformance in the market [3] Performance Metrics - Over the past week, EYPT shares increased by 9.01%, while the Zacks Medical - Biomedical and Genetics industry declined by 1.33% [5] - In a longer timeframe, EYPT's shares rose by 27.41% over the past month, significantly outperforming the industry's 0.8% [5] - For the last three months, EYPT shares have increased by 25.4%, and over the past year, they have surged by 145.49%, compared to the S&P 500's gains of 2.85% and 17.84%, respectively [6] Trading Volume - EYPT's average 20-day trading volume is 1,226,230 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the past two months, three earnings estimates for EYPT have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from -$3.06 to -$3.00 [9] - For the next fiscal year, three estimates have also moved upwards with no downward revisions [9] Conclusion - Given the strong performance metrics and positive earnings outlook, EYPT is positioned as a solid momentum pick with a Momentum Score of A and a Zacks Rank of 2 (Buy) [11]

Core Insights - Halozyme Therapeutics (HALO) has shown a significant upward movement in its stock price following the release of better-than-expected financial results for its third quarter, indicating a positive market reaction to the company's performance [1]. Company Summary - Halozyme Therapeutics specializes in medical technology and collaborates with major pharmaceutical companies such as Johnson & Johnson (JNJ), Bristol Myers Squibb (BMY), and Roche (RHHBY) by providing drug delivery technology in exchange for royalties [1]. Market Performance - The stock of Halozyme Therapeutics is climbing off the bottom of a consolidation pattern, suggesting a potential for further growth and possibly reaching record highs in the near future [4].

Group 1 - EyePoint Pharmaceuticals reported a quarterly loss of $0.65 per share, which aligns with the Zacks Consensus Estimate, compared to a loss of $0.55 per share a year ago [1] - The company posted revenues of $24.45 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 345.17%, and up from $11.68 million year-over-year [2] - The stock has underperformed, losing about 16.1% since the beginning of the year, while the S&P 500 declined by 4.7% [3] Group 2 - The earnings outlook for EyePoint Pharmaceuticals is mixed, with the current consensus EPS estimate for the coming quarter at -$0.67 on revenues of $5.49 million, and -$2.84 on revenues of $13.96 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which EyePoint Pharmaceuticals belongs, is currently in the top 35% of Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The estimate revisions trend for EyePoint Pharmaceuticals is currently reflected in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]